Health Care & Life Sciences » Pharmaceuticals | Celltrion Pharm Inc.

Celltrion Pharm Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
52,657
66,744
74,732
104,811
135,860
Cost of Goods Sold (COGS) incl. D&A
17,478
23,879
27,713
53,905
83,449
Gross Income
35,179
42,866
47,019
50,906
52,411
SG&A Expense
27,532
34,561
40,662
43,718
47,949
EBIT
7,647
8,305
6,357
7,189
4,462
Unusual Expense
269
373
-
-
1,443
Non Operating Income/Expense
2,696
104
32
15
768
Interest Expense
1,444
3,076
6,691
6,711
5,475
Pretax Income
3,622
5,910
1,060
572
3,128
Income Tax
1,009
40
5,674
2,344
251
Consolidated Net Income
2,613
5,869
6,734
2,916
2,877
Net Income
2,613
5,869
6,734
2,916
2,877
Net Income After Extraordinaries
2,613
5,869
6,734
2,916
2,877
Net Income Available to Common
2,613
5,869
6,734
2,916
2,877
EPS (Basic)
157.99
349.01
309.99
107.84
86.00
Basic Shares Outstanding
17
17
22
27
34
EPS (Diluted)
158.30
331.03
282.82
107.67
85.73
Diluted Shares Outstanding
17
18
32
27
34
EBITDA
8,698
9,492
7,823
19,602
21,320
Non-Operating Interest Income
384
412
1,425
109
97

About Celltrion Pharm

View Profile
Address
82 2sandan-ro
Cheongju-si NC 28117
Korea, Republic Of
Employees -
Website http://www.celltrionph.com
Updated 09/14/2018
Celltrion Pharm, Inc. engages in the manufacture and sale of pharmaceuticals. Its products are categorized into the following: the group of medicine effect, biosimilars and over-the-counter (OTC) drug. The group of medicine effect includes hepatotonics, hepatotonics and anti-inflammatory drugs, antihistamine, respiratory apparatus drugs, circulatory system drug, digestives and stomachics drug, hormone and metabolic disease drugs, antibiotics and antimycotic, nutrientia and tonic, immunology, oncology, and the other drugs.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.